検索結果

で失明の主 な原因となっています 8。日本では、約 10 万人が罹患していると推定されており、これまでに承認された治療法はありません でした 2,3。 参考文献 1 Boyer DS, et al. The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the comp...

千寿製薬について | 千寿製薬株式会社

CEO Message Management Policy Company Profile Our Initiatives for Society / Environment Business Activities Production system Quality policy

发表论文 | 研究与开发 | 千寿制药株式会社

zed, Double-Masked, Dose-Finding Study Yuichi Hori1, Tomoyuki Wada2, Kazunori Omatsu2, on behalf of the SJP-0132 clinical study investigators 1: Department of Ophthalmology, Toho University Faculty of...

Presence of Products | Overseas Activities | SENJU Pharmaceutical

Name Marketing Authorisation Holder JP Brand Name YELLOX Bausch + Lomb Poland Sp. z o.o. BRONUCK Netherland Brand Name Marketing Authorisation Holder JP Brand Name YELLOX Bausch + Lomb Poland Sp. z o...

Ltd. Launch and Distribution of “MIEr for ImageFS” Senju Pharmaceutical Co., Ltd., hereby announces the commercial launch and distribution of “MIEr for ImageFS” in Japan. MIEr for ImageFS can sharpen ...